IN THIS MONTH'S ISSUE:
July 2017

Valbenazine (Ingrezza): The First Drug Approved to Treat TD
Valbenazine (Ingrezza), an inhibitor of vesicular monoamine transporter 2 (VMAT2), is the first medication approved by the FDA to treat tardive dyskinesia.

A Dietary Supplement to Reduce the Risk of Postpartum Depression?
In a small, open-label trial, a dietary supplement decreased the propensity for sadness in postpartum women.

Pimavanserin (Nuplazid) for Parkinson Disease Psychosis
Pimavanserin (Nuplazid), a new molecular entity, is the first drug approved by the FDA to treat Parkinson disease psychosis.

In Brief
Review Finds that Dietary Supplements and Special Diets Do Not Improve Autism Symptoms; Aerobic Exercise Improves Executive Function in Adults with Vascular Cognitive Impairment

Don't Forget Clozapine
A recent survey found that US residents are hesitant to prescribe clozapine (Clozaril and others) for patients with schizophrenia, citing fear of side effects and lack of sufficient training on how to properly prescribe and monitor clozapine treatment.

Register for FREE Online Access

Please fill in the information requested below to start your free online subscription! All fields marked with a red asterisk (*) are required.

Your Contact Information


If you do not live in the United States or Canada, please select "none" for state.
  
Login Information

(Your email address is your user name)
Residency Director Information
(For resident status verification)
  
Residency Information
 
* denotes required fields.